Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Sinha Uma	2. Issuer Name and Ticker or Trading Symbol Eidos Therapeutics, Inc. [ EIDX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Scientific Officer
(Last)          (First)          (Middle) C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2000	3. Date of Earliest Transaction (MM/DD/YYYY) 1/13/2021
(Street) SAN FRANCISCO, CA 94104 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	1/13/2021		S(1)		696	D	$121.1094 (2)	315829	D
Common Stock	1/13/2021		S(1)		572	D	$122.2667 (3)	315257	D
Common Stock	1/13/2021		S(1)		1498	D	$123.4787 (4)	313759	D
Common Stock	1/13/2021		S(1)		4934	D	$124.7187 (5)	308825	D
Common Stock	1/13/2021		S(1)		2000	D	$125.35 (6)	306825	D
Common Stock	1/13/2021		S(1)		300	D	$126.39 (7)	306525	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020.
(2)	Represents the weighted average sale price of the shares sold ranging from $120.81 to $121.33 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7.
(3)	Represents the weighted average sale price of the shares sold ranging from $121.98 to $122.89 per share.
(4)	Represents the weighted average sale price of the shares sold ranging from $123.01 to $124.00 per share.
(5)	Represents the weighted average sale price of the shares sold ranging from $124.10 to $125.09 per share.
(6)	Represents the weighted average sale price of the shares sold ranging from $125.11 to $125.66 per share.
(7)	Represents the weighted average sale price of the shares sold ranging from $126.30 to $126.57 per share.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Sinha Uma C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO, CA 94104	X		Chief Scientific Officer

Signatures
/s/ Franco Valle, Attorney-in-Fact		1/14/2021
**Signature of Reporting Person		Date